Stocks Health care NSPR
NASDAQ · Health careInspireMD, Inc. (NSPR)
InspireMD, Inc. brought in $10.8M of revenue over the twelve months to June 30, 2026, up 53.4% from a year earlier. It posted a net loss of $52.5M. In fiscal 2025 capital spending exceeded operating cash flow by $36.8M. At June 30, 2026 it held $15.1M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 14, 2026.
Key facts about InspireMD, Inc.
- Net worth
- InspireMD, Inc. has a market value (market cap) of $33.1M at the latest share price, and shareholders' equity of $31.5M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $9M (+28.1% year on year), with a net loss of $48.8M. Over the 12 months to June 30, 2026: revenue $10.8M, net loss $52.5M.
- Cash flow
- In fiscal 2025 operations used $35.1M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 14, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- InspireMD, Inc.'s next report was expected around November 3, 2026 and is not on file with the SEC yet.
What InspireMD, Inc. does
InspireMD, Inc. is registered with the SEC under industry code SIC 3841 (Surgical & Medical Instruments & Apparatus). Its shares trade on NASDAQ under the ticker NSPR.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $9M | -$48.8M | -$0.76 | -$36.8M |
| 2024 | $7M | -$32M | -$0.76 | -$23.3M |
| 2023 | $6.2M | -$19.9M | -$0.82 | -$16.8M |
| 2022 | $5.2M | -$18.5M | -$2.35 | -$16M |
| 2021 | $4.5M | -$14.9M | -$2.03 | -$13.6M |
| 2020 | $2.5M | -$10.5M | -$6.97 | -$9.2M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where NSPR ranks in Health care
Latest SEC filings
What InspireMD, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 21, 2026Material agreement8-KInspireMD amended terms for certain Series J and Series K warrants to reduce the exercise price and align expiration with expected FDA approval.
- August 17, 2026
- August 14, 2026Quarterly report 10-Q · period to June 30, 2026Revenue was flat at $1.8M versus the same quarter last year; diluted EPS -$0.17 versus -$0.26.
- July 29, 2026
- July 23, 2026
- July 2, 2026
- June 11, 2026
- June 3, 2026
- May 22, 2026
- May 15, 2026Passive stake changed SCHEDULE 13G/A
Insider trades
What the people running InspireMD, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| May 27, 2026 | Stuka PaulDirector | Bought | 20,000 | $17.5K |
| May 19, 2026 | Gleason Shane ThomasChief Commercial Officer | Sold | 22,778 | $23K |
| May 14, 2026 | Stuka PaulDirector | Bought | 5,000 | $5.8K |
| May 13, 2026 | Stuka PaulDirector | Bought | 10,000 | $11.6K |
| May 12, 2026 | Slosman MarvinCEO and President, Director | Bought | 21,000 | $25.2K |
| May 11, 2026 | Stuka PaulDirector | Bought | 10,000 | $11.9K |
| May 8, 2026 | Stuka PaulDirector | Bought | 65,626 | $76.1K |
| May 7, 2026 | Roubin Gary SDirector | Bought | 90,000 | $106.2K |
Who owns NSPR
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Marshall Wace, Llp13G, passive | 9.99% | November 14, 2025 |
| Nantahala Capital Management, LLC13G, passive with 2 related filers | 9.99% | May 15, 2026 |
| Rosalind Advisors, Inc.13G, passive with 4 related filers | 9.2% | February 11, 2026 |
| Michael A. Lawless13D, may seek influence | 8.6% | October 29, 2025 |
| Aberdeen Group plc13G, passive with 1 related filers | 7.49% | February 2, 2026 |
| Orbimed Advisors LLC13G, passive with 1 related filers | 7.4% | February 17, 2026 |
| Parkman Healthcare Partners LLC13G, passive with 3 related filers | 5.8% | November 14, 2025 |
| Nantahala Capital Partners Limited Partnership13G, passive | 5.68% | November 14, 2025 |
| Marvin Slosman13D, may seek influence | 5.18% | April 24, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 37 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Nantahala Capital Management, LLC | 6,752,968 | +3,376,484 |
| Rosalind Advisors, Inc. | 3,905,743 | 0 |
| Aberdeen Group plc | 3,698,364 | +525,000 |
| Orbimed Advisors LLC | 3,133,405 | 0 |
| Parkman Healthcare Partners LLC | 2,416,518 | 0 |
| Marshall Wace, Llp | 1,860,405 | 0 |
| Soleus Capital Management, L.P. | 1,045,708 | 0 |
| Pura Vida Investments, LLC | 450,517 | 0 |
| Affiance Financial, LLC | 250,370 | 0 |
| Velan Capital Investment Management LP | 148,138 | -1,951,514 |
| BlackRock, Inc. | 122,993 | +42,544 |
| Renaissance Technologies LLC | 112,832 | +95,223 |
| Creative Planning | 108,964 | +89,250 |
| Schonfeld Strategic Advisors LLC | 99,275 | new |
| XTX Topco Ltd | 49,029 | +36,671 |
| Centiva Capital, LP | 44,123 | +19,357 |
| Millennium Management LLC | 37,677 | -74,746 |
| Courier Capital LLC | 30,000 | 0 |
| Mesirow Financial Investment Management, Inc. | 30,000 | 0 |
| Morgan Stanley | 28,371 | -11,465 |
Insiders
11 insiders reported holding 12,381,864 shares in total, about $8.8M at the last price.
| Holder | Shares |
|---|---|
| Slosman MarvinCEO and President, Director | 7,092,316 |
| Gleason Shane ThomasChief Commercial Officer | 1,053,882 |
| Tommasoli AndreaChief Operating Officer | 954,389 |
| Roubin Gary SDirector | 834,478 |
| Lawless Michael AChief Financial Officer | 691,695 |
| Stuka PaulDirector | 667,871 |
| Berman MichaelDirector | 352,586 |
| Arnold KathrynDirector | 303,087 |
| Ward Scott R.Director | 237,096 |
| Dearen Danny L.Director | 102,047 |
Questions about NSPR
What does InspireMD, Inc. do?
InspireMD, Inc. is a company in the Health care sector, listed on NASDAQ as NSPR. Its shares trade on NASDAQ under the ticker NSPR.
What is InspireMD, Inc.'s net worth?
InspireMD, Inc. has a market value (market cap) of $33.1M at the latest share price, and shareholders' equity of $31.5M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is InspireMD, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $52.5M on revenue of $10.8M.
How much revenue does InspireMD, Inc. make?
Over the twelve months to June 30, 2026 InspireMD, Inc. reported revenue of $10.8M. That is 53.4% more than a year earlier.
When did InspireMD, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 14, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the insider trade from September 23, 2026.
When is InspireMD, Inc.'s next earnings report?
InspireMD, Inc.'s next report was expected around November 3, 2026 and is not on file with the SEC yet.
Similar companies
Compare NSPR with
Follow NSPR
Get an email when InspireMD, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values InspireMD, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.